English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixir's metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold.Methods: The DESolve FIM trial enrolled 15 patients, treated with a single 3.0x14 mm DESolve at 3 centers. IVUS was performed at the end of the procedure and repeated at six-month invasive follow-up. Complete and adequate IVUS images at baseline and follow-up were obtained for 11 cases. Serial changes in vessel volume, scaffold area and the degree of NIH formation were assessed. All analyses were performed by an independent core laboratory.Results: From baseline to 6 months, IVUS showed a small increase in scaffold mean area (from 5.35±0.78mm2 to 5.61±0.81mm2). Additionally, there was no significant change in vessel volume (from 148.0±37.0 mm3 to 150.03±35.38 mm3) or area, demonstrating the absence of constrictive or expansive remodelling. There was very low neointimal volume (5.6±2.8 mm3) and % scaffold obstruction (7.18±3.37%) and no cases of incomplete strut apposition. Also no scaffold discontinuity (e.g.: fracture) was observed in this sample.Conclusions: The DESolve scaffold demonstrated a unique property of expansion and no chronic recoil from baseline to follow-up. Results at 6 months showed effective neointimal suppression and no late strut malapposition thus suggesting a very efficacious and novel bioresorbable scaffold.

Six-month intravascular ultrasound analysis of the DESolve FIM Trial with a novel PLLA-based fully biodegradable drug-eluting Scaffold